July 2014 PBAC OUTCOMES - Deferrals Drug Name, form(s), strength(s), Sponsor, Type of submission Drug Type and Use - Ruxolitinib - Document - PDFSEARCH.IO

First Page	Meta Content
	July 2014 PBAC OUTCOMES - Deferrals Drug Name, form(s), strength(s), Sponsor, Type of submission Drug Type and Use Add to Reading List Document Date: 2015-01-19 17:21:09 Open Document File Size: 50,02 KB Share Result on Facebook Company Novartis Pharmaceuticals Australia Pty Ltd / Janssen-Cilag Pty Ltd / Human Services / / MedicalCondition chronic plaque psoriasis / diabetes mellitus / disease / thrombocytopenia episode / spondylitis / Crohn disease / Rheumatoid arthritis / line diabetes / psoriatic arthritis / diabetes / myelofibrosis / / Organization Pharmaceutical Benefits Advisory Committee / Department of Human Services / Department of Health Change / Myelofibrosis Authority / / Product Remicade / glucagon / / SocialTag Pharmacology Medicine Healthcare in Australia Pharmaceutical Benefits Scheme Pharmaceuticals policy Health Ruxolitinib Infliximab Ustekinumab Immunosuppressants

July 2014 PBAC OUTCOMES - Deferrals Drug Name, form(s), strength(s), Sponsor, Type of submission Drug Type and UseAdd to Reading List